Plasma cell leukemia: update on biology and therapy

被引：35

作者：

Mina, Roberto ^{[1
]}

D'Agostino, Mattia ^{[1
]}

Cerrato, Chiara ^{[1
]}

Gay, Francesca ^{[1
]}

Palumbo, Antonio ^{[1
]}

机构：

[1] Azienda Osped Univ Citta Salute & Sci Torino, Myeloma Unit, Div Hematol, Turin, Italy

来源：

LEUKEMIA & LYMPHOMA | 2017年 / 58卷 / 07期

关键词：

Plasma cell leukemia; primary PCL; secondary PCL; autologous stem cell transplantation; novel agents; MULTIPLE-MYELOMA; INTERGROUPE-FRANCOPHONE; GENETIC ABERRATIONS; BORTEZOMIB; SURVIVAL; DEXAMETHASONE; TRANSPLANTATION; LENALIDOMIDE; THALIDOMIDE; CYCLOPHOSPHAMIDE;

D O I：

10.1080/10428194.2016.1250263

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Plasma cell leukemia (PCL) is a rare, but very aggressive, plasma cell dyscrasia, representing a distinct clinicopathological entity as compared to multiple myeloma (MM), with peculiar biological and clinical features. A hundred times rarer than MM, the disease course is characterized by short remissions and poor survival. PCL is defined by an increased percentage (>20%) and absolute number (> 2 x 10(9)/l) of plasma cells in the peripheral blood. PCL is defined as 'primary' when peripheral plasmacytosis is detected at diagnosis, 'secondary' when leukemization occurs in a patient with preexisting MM. Novel agents have revolutionized the outcomes of MM patients and have been introduced also for the treatment of PCL. Here, we provide an update on biology and treatment options for PCL.

引用

页码：1538 / 1547

页数：10

共 66 条

[61] The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2 [J].

Stott, FJ ;

Bates, S ;

James, MC ;

McConnell, BB ;

Starborg, M ;

Brookes, S ;

Palmero, I ;

Ryan, K ;

Hara, E ;

Vousden, KH ;

Peters, G .

EMBO JOURNAL, 1998, 17 (17) :5001-5014

[62] Genetic aberrations and survival in plasma cell leukemia [J].

Tiedemann, R. E. ;

Gonzalez-Paz, N. ;

Kyle, R. A. ;

Santana-Davila, R. ;

Price-Troska, T. ;

Van Wier, S. A. ;

Chng, W. J. ;

Ketterling, R. P. ;

Gertz, M. A. ;

Henderson, K. ;

Greipp, P. R. ;

Dispenzieri, A. ;

Lacy, M. Q. ;

Rajkumar, S. V. ;

Bergsagel, P. L. ;

Stewart, A. K. ;

Fonseca, R. .

LEUKEMIA, 2008, 22 (05) :1044-1052

[63] Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome [J].

Todoerti, Katia ;

Agnelli, Luca ;

Fabris, Sonia ;

Lionetti, Marta ;

Tuana, Giacomo ;

Mosca, Laura ;

Lombardi, Luigia ;

Grieco, Vitina ;

Bianchino, Gabriella ;

D'Auria, Fiorella ;

Statuto, Teodora ;

Mazzoccoli, Carmela ;

De Luca, Luciana ;

Petrucci, Maria Teresa ;

Morabito, Fortunato ;

Offidani, Massimo ;

Di Raimondo, Francesco ;

Falcone, Antonietta ;

Omede, Paola ;

Tassone, Pierfrancesco ;

Boccadoro, Mario ;

Palumbo, Antonio ;

Neri, Antonino ;

Musto, Pellegrino .

CLINICAL CANCER RESEARCH, 2013, 19 (12) :3247-3258

[64] Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols [J].

Usmani, S. Z. ;

Nair, B. ;

Qu, P. ;

Hansen, E. ;

Zhang, Q. ;

Petty, N. ;

Waheed, S. ;

Shaughnessy, J. D., Jr. ;

Alsayed, Y. ;

Heuck, C. J. ;

Van Rhee, F. ;

Milner, T. ;

Hoering, A. ;

Szymonifka, J. ;

Sexton, R. ;

Sawyer, J. ;

Singh, Z. ;

Crowley, J. ;

Barlogie, B. .

LEUKEMIA, 2012, 26 (11) :2398-2405

[65] How I treat plasma cell leukemia [J].

van de Donk, Niels W. C. J. ;

Lokhorst, Henk M. ;

Anderson, Kenneth C. ;

Richardson, Paul G. .

BLOOD, 2012, 120 (12) :2376-2389

[66] In-Vitro Actvity of Pixantrone (PIX) in Plasma Cell Leukaemia (PCL) and Early Clinical Activity in a Pixantrone-Pomalidomide-Dexamethasone (PiPoD) Combination [J].

Willenbacher, Ella ;

Willenbacher, Wolfgang ;

Gastl, Gunther ;

Verdorfer, Irmgard ;

Kircher, Brigitte .

BLOOD, 2014, 124 (21)

← 1 2 3 4 5 6 7 →